Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17543185 | 0.92 | LMNA (0.44) | NPC1RAB9AFLT3ATMLMNA | |
| SCHEMBL12684501 | 0.83 | MAPK8 (0.41) | NPC1RAB9ALMNAHSD17B10ALDH1A1 | |
| SCHEMBL237952 | 0.83 | LGMN (0.43) | NPC1RAB9AFLT3LMNAPOLB | |
| SCHEMBL17544071 | 0.81 | SMN1; SMN2 (0.40) | FLT3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17543831 | 0.80 | POLB (0.45) | NPC1RAB9AATMLMNAPOLB | |
| SCHEMBL29931972 | 0.80 | ATM (0.48) | NPC1RAB9AFLT3ATMLMNA | |
| SCHEMBL17543165 | 0.80 | ATM (0.48) | NPC1RAB9AFLT3ATMLMNA | |
| SCHEMBL15458277 | 0.80 | NPC1 (0.41) | NPC1RAB9AATMLMNAPOLB | |
| SCHEMBL14336803 | 0.77 | CHRM2 (0.48) | NPC1RAB9AATMLMNATP53 | |
| SCHEMBL17543781 | 0.77 | NPC1 (0.36) | NPC1RAB9AFLT3LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589448-A | 3, 4-dihydroquinolinone derivative and application thereof | 西南交通大学 | 2023-08-15 | — | — | CN | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-108884044-B | Piperidine derivatives | 大塚制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| WO-2017146246-A1 | PIPERIDINE DERIVATIVE | 大塚製薬株式会社 | 2017-08-31 | — | — | WO | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | NPC1 2197/4885RAB9A 682/4885FLT3 3774/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | NPC1 2197/4885RAB9A 682/4885FLT3 3774/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | NPC1 2197/4885RAB9A 682/4885FLT3 3774/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | NPC1 2197/4885RAB9A 682/4885FLT3 3774/4885 |
| US-10851079-B2 | Piperidine derivative | EP300, SLC11A2, TBC1D5 | NPC1 3278/4885RAB9A 352/4885FLT3 2429/4885 |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | EP300, SLC11A2, TBC1D5 | NPC1 3278/4885RAB9A 352/4885FLT3 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.